𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Azathioprine Maintains first remission in newly diagnosed pediatric Crohn's disease

✍ Scribed by Gerald J. Jaspers; Henkjan J. Verkade; Johanna C. Escher; Lissy de Ridder; Jan A. J. M. Taminiau; Edmond H. H. M. Rings


Book ID
110087422
Publisher
John Wiley and Sons
Year
2006
Tongue
English
Weight
176 KB
Volume
12
Category
Article
ISSN
1078-0998

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


Tolerance and efficacy of azathioprine i
✍ Laura Riello; CΓ©cile Talbotec; HΓ©lΓ¨ne Garnier-LenglinΓ©; BΓ©nΓ©dicte Pigneur; Johan πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 131 KB πŸ‘ 2 views

## Background: Thiopurines are considered first-line immunomodulators for the prevention of relapse in moderate to severe pediatric crohn's disease (cd). early introduction of thiopurines was shown in a pediatric trial to maintain steroid-free remission in 90% of patients for 18 months. in the pres

Azathioprine is superior to budesonide i
✍ Gerassimos J. Mantzaris; Angeliki Christidou; Michael Sfakianakis; Anastassios R πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 157 KB πŸ‘ 1 views

## Background: The effects of azathioprine (AZA) and budesonide (BUD) on mucosal healing and histologic remission of Crohn's disease (CD) are insufficiently studied. In this prospective study we evaluated the comparative effects of AZA and BUD on endoscopic and histologic activity in patients with

Course and treatment of perianal disease
✍ David J. Keljo; James Markowitz; Christine Langton; Trudy Lerer; Athos Bousvaros πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 85 KB πŸ‘ 2 views

## Background: We sought to characterize perianal disease and its treatment in pediatric patients newly diagnosed with crohn's disease. ## Methods: Data were obtained from the pediatric inflammatory bowel disease (ibd) collaborative group registry, a prospective, multicenter observational registr